The aim of our research is to evaluate the rate, the type, the severity, the causative factors, and the pathogenesis of complications during the course of myelodysplastic syndromes (MDS). Complications among MDS patients on outpatient management were prospectively recorded and classified. During an 18-month observation period, complications emerging in 48 outpatients with MDS, of whom 15 (31%) were on active treatment and 33 (69%) were receiving best supportive care alone, were recorded and analyzed. Out of 48 patients (median age, 72 years), 34 (71%) experienced complications; a total number of 92 events were recorded; most frequently observed events were infections (43 events, 47%) and bleeding (11 events, 12%). Complications are a frequent issue in MDS; preventive measures should be directed toward the most frequently observed complications.
LevisA. Sindromi mielodisplastiche: un problema prevalentemente dell’anziano [Rilevazioni epidemiologiche del Registro Piemontese]. Ital J Med. 2010;4(3, Speciale 1-2).
2.
GreenbergPLAttarEBennettJ. M.. Myelodysplastic syndromes. J Natl Compr Canc Netw. 2011;9(1):30-56.
3.
SekeresMASchoonenWMKantarjianH. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst. 2008;100(21):1542-1551.
4.
SantiniVAlessandrinoPEAngelucciE. Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leuk Res. 2010;34(12):1576-1588.
5.
GreenbergPCoxCLeBeauMM. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6):2079-2088.
6.
SantiniVFenauxPMuftiGJ. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine. Eur J Haematol. 2010;85(2):130-138.
7.
SilvermanLRDemakosEPPetersonBL. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20(10):2429-2440.
8.
FenauxPMuftiGJHellstrom-LindbergE. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-232.
9.
BuccisanoFMuftiGJHellstrom-LindbergE. Thoracic cord compression caused by epidural extramedullary hematopoiesis during erythroid-stimulating agent therapy in two patients with myelodysplastic syndromes. J Clin Oncol. 2013:31(11):e189-e191. doi:10.1200/JCO.2012;45.3209.
10.
NiscolaPTendasAScaramucciL. Gingival myeloid sarcoma in myelodysplastic syndrome. Support Care Cancer. 2013;21(4):917-918. doi:10.1007/s00520-012-1702-6.
11.
TrottiAColevasADSetserA. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176-181.
ListADewaldGBennettJ. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456-1465.
15.
TendasANiscolaPCinqueR. Motor disability in malignant hematology: an epidemiological study on Italian hospitalized patients. Leuk Res. 2010;34(2):e66.
16.
TendasANiscolaPAlesM. Disability and physical rehabilitation in patients with advanced hematological malignancies followed in a home care program. Support Care Cancer. 2009;17(12):1559-1560.
17.
ScaramucciLTendasANiscolaP. Motor disability in the setting of oral anticoagulant therapy. Int J Hematol. 2011;94(5):499-500.
18.
DayyaniFConleyAPStromSS. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer. 2010;116(9):2174-2179.
19.
DuhMSModySHLefebvrePWoodmanRCButeauSPiechCT. Anaemia and the risk of injurious falls in a community-dwelling elderly population. Drugs Aging. 2008;25(4):325-334.
20.
CaocciGLa NasaGEfficaceF. Health-related quality of life and symptom assessment in patients with myelodysplastic syndromes. Expert Rev Hematol. 2009;2(1):69-80.
